VARIAN MEDICAL SYSTEMS JP Morgan Healthcare Conference -

Similar documents
2015 ASTRO INVESTOR MEETING. October 20, 2015

Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014

Press release Regulated information

Philips Healthcare overview. Steve Rusckowski CEO Philips Healthcare

PROTON THERAPY. Proton Therapy World Market Report Edition 2015 WORLD MARKET REPORT EDITION MEDraysintell

The Future of Consumer Health Care

Nokia Conference Call Third Quarter 2004 Financial Results. Jorma Ollila Chairman and CEO Rick Simonson Senior Vice President and CFO

Elekta Full-year report 2014/15

Third Quarter 2015 Conference Call

Jay Hoey. Executive Vice President. Region North America

First Quarter 2016 Conference Call

Proton Therapy - Frequently Asked Questions For Clinicians

Paul Smit CA Chevreux, March 16, 2006 Paris

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED

With the project we hope to bring enhanced treatment for better care of our patients who will no

Varian Medical Systems: Maximizing the Speed of Mobile Apps with SAP Enterprise Support

Game-Changing Industry Leadership

Abbott Diagnostics. Durable Growth Business

Health Care Worldwide

Medical Billing - The Government's Big Hammer

2015 Second Quarter Business Review (unaudited) July 23, 2015

PROTON THERAPY THE UP-AND-COMING MARKET! The Corporate Strategic Intelligence you need!

Proton Therapy System A NEW WAY TO DO WHAT YOU DO BEST FIGHT CANCER

SpeeCo Acquisition Overview. August 10, 2010

ARIA ONCOLOGY INFORMATION SYSTEM RADIATION ONCOLOGY

DISCOVER ASCOM S EXCITING BUSINESS FRITZ MUMENTHALER, CEO

Accreditation a tool to help reduce medical errors. Professor Arthur T Porter PC MD FACR FRCPC FACRO

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015

Slide 1, Opening Matt Ginter, Treasurer and Vice President, Investor Relations

Training & Education Solutions

compared to the fourth quarter of 2006, the third quarter of 2007, and to the year ended

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Enhancing Value With Financial & Operational Excellence

Investor Presentation. Acquisition. LCA-Vision. February 14, 2014

An introduction to Optos

Department of Radiation Oncology

GE Technology Infrastructure John Rice Vice Chairman & CEO August 5 th, 2010

RADIATION THERAPY FOR BRAIN METASTASES. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

SAFE HARBOR STATEMENT

Morgan Stanley Leveraged Finance Conference

Orbitz Worldwide, Inc.

Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.

Introduction. Now, I ll turn the call over to Mark Loughridge.

FY2010 Results Presentation. 23 March 2011

FIRST QUARTER REPORT

FAQ About Prostate Cancer Treatment and SpaceOAR System

Q1 Fiscal Year 2016 Earnings Conference Call

J.P. Morgan Global High Yield & Leveraged Finance Conference. February 26, 2014

ASML reports Q3 results as guided and remains on track for record 2015 sales Two new lithography scanners launched

Corporate Profile. Quarterly Highlights. Financial Review. Operation Highlights

Diodes Incorporated Reports Record Fourth Quarter and Full Year 2005 Results

Safe Harbor Provision

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private

Basic Radiation Therapy Terms

PRESENTATION OF FOURTH QUARTER Oslo 12 February 2015 CEO Thomas Falck and CFO Roar Østbø

First Three Years After Project Proton Therapy Facility:

Proton Therapy in Singapore

Global Technology Services. Mike Daniels Senior Vice President Global Technology Services

TomTom Q results. Harold Goddijn CEO Marina Wyatt CFO 12 February 2013

Sierra Wireless Reports Second Quarter 2015 Results

Fourth. Quarter Report. Full year

A LEADING GLOBAL HEALTHCARE COMPANY

IBM REPORTS 2013 FOURTH-QUARTER AND FULL-YEAR RESULTS

Life & Protection. Scott Ham CEO. John Hunter COO. Analyst & Investor Conference

CONFERENCE CALL Q1/2016 RESULTS. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Q3 Fiscal Year 2015 Earnings Conference Call

Fourth Quarter 2015 Conference Call

Regal Beloit Corporation Third Quarter 2014 Earnings Conference Call

ARIA. Oncology Information System

FRANKLIN ELECTRIC REPORTS RECORD SECOND QUARTER 2013 SALES AND EARNINGS

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

Strong Q2 Outlook increased

ARIA. Oncology Information System

Verifone Reports Results for the Second Quarter of Fiscal 2016

How To Understand How Well-Run A Company Like Aerocean Does Well

In 1946 Harvard physicist Robert Wilson ( ) suggested:

Unilever First Half 2015 Results Paul Polman / Jean-Marc Huët 23 rd July 2015

FOURTH QUARTER REPORT 2007

FREQUENTLY ASKED QUESTIONS

Forward Looking Statement

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.

Radiation Therapy in Prostate Cancer Current Status and New Advances

Regal Beloit Corporation Second Quarter 2014 Earnings Conference Call

Accenture Reports Third-Quarter Fiscal 2015 Results. -- Revenues of $7.8 billion, up 0.4% in U.S. dollars and 10% in local currency --

American Tower Corporation: An Overview. June 2014

SAP The World s Leading Business Software Company

SECOND QUARTER & SIX MONTHS 2015 CONFERENCE CALL AND WEBCAST NYSE:DDD

ELEKTA AB (publ) Interim report for the three months ended July 31, 2001

Willis Group Holdings. February 2014 I Bank of America Merrill Lynch Insurance Conference

The Center for Cancer Care. Comprehensive and compassionate care

Health Care Worldwide

Third quarter 2015 revenue

Financial Information

FULL YEAR RESULTS 2015 YEAR ENDED 30 JUNE 2015

Baader Investment Conference. Dr. Werner Brandt, CFO, SAP AG Munich, September 24, 2013

International Sales & Marketing Jie LIU Executive Vice President, International Sales & Marketing 2007 Analyst & Investor Day

Ericsson Fall Capital Markets Day,San Diego November

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013

Credit Suisse Global Health Care Conference. March 5, 2013

First-Quarter 2014 Financial Results

Transcription:

VARIAN MEDICAL SYSTEMS JP Morgan Healthcare Conference - Dow Wilson, CEO January 13, 2015 January 2015 2015 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED.

Forward-Looking Statements Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as our Edge radiosurgery system, TrueBeam and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms could, believe, expect, outlook, or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company s actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company s products; the company s ability to develop, commercialize, and deploy new products; the company s ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; the company s assessment of the goodwill associated with its particle therapy business, challenges associated with the successful commercialization of the company s particle therapy business; the effect of adverse publicity; the company s reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products; the company s ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this presentation because of new information, future events, or otherwise. 2 VARIAN MEDICAL SYSTEMS

Technology Leader in Growing Markets Varian Oncology Systems Radiotherapy Radiosurgery Brachytherapy Varian Imaging Components X-Ray Tubes Digital Flat Panels Security & Inspection Products Varian Particle Therapy Proton therapy 3 VARIAN MEDICAL SYSTEMS

OUR VISION: TO HELP SAVE MILLIONS OF LIVES EVERY YEAR, EVERYWHERE. 4 VARIAN MEDICAL SYSTEMS

FY15 Focus on Our Big 5 Strategic Priorities Go Global Grow Software and Services Innovate Commercialize Protons Drive Operational Excellence 5 VARIAN MEDICAL SYSTEMS

Oncology Systems 6 VARIAN MEDICAL SYSTEMS

The Global Economic Cancer Burden Nations investing more to fight growing cancer burden $895B 27M New cases annually by 2050 17.5M Deaths annually cancer cost *Economic losses from disability and premature deaths. Excludes direct medical costs Sources: American Cancer Society, Livestrong, World Health Organization 7 VARIAN MEDICAL SYSTEMS

People 60 Years and Older ( in Millions) Cancer Needs Growing with Aging Populations 1400 1200 1000 800 600 400 >80% Rise in world population over 60 200 0 Source: U.S. Census Bureau 2010 2030 8 VARIAN MEDICAL SYSTEMS

10,000+ Linacs Needed Number of radiotherapy machines per million people No machines Less than 1 5 or less 10 or more 9 VARIAN MEDICAL SYSTEMS

7,500 Varian Accelerators 60% of global installed base 2.8M patients treated annually 10 VARIAN MEDICAL SYSTEMS 10

Americas Market Drivers in 2015 North America - Shift to SRS driving replacements - Reimbursement helping - Productivity initiatives/software - Service growth Latin America - Equipment shortage - Demand for quality care 11 VARIAN MEDICAL SYSTEMS

EMEA Market Drivers in 2015 Aging installed base Focus on productivity Emerging markets India, Eastern Europe, Africa SRS adoption lung, liver 12 VARIAN MEDICAL SYSTEMS

APAC Market Drivers in 2015 Increased use of RT China (20%), Japan (28%) Software/Service Expansion Focus on Value Service Agreements 13 VARIAN MEDICAL SYSTEMS

New Products Drive Growth 45% of FY2014 orders came from products introduced in the last 5 years 14 VARIAN MEDICAL SYSTEMS

Promising SBRT Results in Lung Study "Technologies have developed in the last few years that have yielded game-changing, paradigm-shifting approaches, allowing us to reconsider how radiation is delivered in combination with surgery, chemotherapy, and other systemic therapies. Dr. Robert Timmerman, UT SW Medical Center 15 VARIAN MEDICAL SYSTEMS

Upgrades Create Growth Opportunity Upgrade 6DOF Couch $440M 5-Year Opportunity RapidArc MLC / PV TrueBeam 2.0 OBI SRS Package 16 VARIAN MEDICAL SYSTEMS

New Products Accelerating Software Growth Oncology Software RapidPlan InSightive Analytics Qumulate QA Velocity RapidPlan $200M 5-Year Opportunity 17 VARIAN MEDICAL SYSTEMS

Growing Oncology Services to $1B 36% of FY14 OS Orders / 40% of FY14 OS Revenues Delivers strong profitability 18 VARIAN MEDICAL SYSTEMS

Long Term Oncology Growth Drivers Demographics Multi-Year Agreements Emerging Markets Service & Software System Upgrades Aging Installations 5-7% Annual Growth Opportunity 19 VARIAN MEDICAL SYSTEMS

Imaging Components 20 VARIAN MEDICAL SYSTEMS

Imaging Components Designs & Manufactures X-ray Tubes Linear Accelerators Workstations Flat Panel Detectors Sells to Equipment Manufacturers Aftermarket Distributors 21 VARIAN MEDICAL SYSTEMS

Imaging Components Market $2.3B Addressable Market Market Medical Imaging Industrial Inspection Cargo and Security Product X-ray Tubes Flat Panels Software X-ray Sources Detectors X-ray Sources Detectors Source: Varian 2014 Market Analysis 22 VARIAN MEDICAL SYSTEMS

Varian Share in Imaging Components Market Diagnostic and CT Tubes Flat Panel Detector 11% 24% 65% Modality OEMs Varian Other 23% 42% Modality OEMs Varian Other 35% 23 VARIAN MEDICAL SYSTEMS

Imaging Growth Initiatives in 2015 Grow with current OEMS Add new customers in Asia, Brazil Extend leadership in tubes, panels with new capabilities Expand software offerings Focus on industrial market Develop/acquire new product lines $400M Potential incremental revenues in 5 Years 24 VARIAN MEDICAL SYSTEMS

Moving to Expand Imaging Portfolio Add image analysis software to imaging product portfolio Offer more complete subsystems with panels/workstations/software Leverage OEM relationships to accelerate market penetration 25 VARIAN MEDICAL SYSTEMS

Long Term Growth Drivers - Imaging Digital Imaging Transition Expanding Product Portfolio Service & Software Emerging Markets/ New Players 7-9% 5-7% Annual Growth Market Growth Opportunity Opp ty 26 VARIAN MEDICAL SYSTEMS 26

Particle Therapy 27 VARIAN MEDICAL SYSTEMS

10 Varian Proton Projects KFMC-King Fahd Medical Center PTC St. Petersburg, Russia Cincinnati Children s Hospital Paul Scherrer Institute National Taiwan University (Taipei) Scripps Proton Therapy Center Rinecker Proton Therapy Center University of Maryland Georgia PT Center (Emory) UT Southwestern Medical Center Booked orders Treating patients Contracted, but not financed, and not booked 28 VARIAN MEDICAL SYSTEMS

Value of protons - lower complications, costs? Head & neck cancer study suggests protons could have lower costs through lower complications Dr. Steven J. Frank, M D Anderson 29 VARIAN MEDICAL SYSTEMS

Proton rationale cost efficiency Proton cancer therapy may cost the same or less than other cancer therapies. MD Anderson breast study using Medicare reimbursement codes 30 VARIAN MEDICAL SYSTEMS

Proton Project Potential $2.5B by 2030 1000 treatment rooms by 2030 Source: MEDraysintell 31 VARIAN MEDICAL SYSTEMS

Proton Market 300 250 200 Cumulative Number of PT Treatment Rooms 150 100 50 0 32 VARIAN MEDICAL SYSTEMS

Long Term Growth Drivers - Protons Demand for Optimal Dose Distribution Evolving Technology Clinical capability Cost efficiency $1.3B 5 Year Market Opp ty 33 VARIAN MEDICAL SYSTEMS

Long-Term Growth Opportunities 34 VARIAN MEDICAL SYSTEMS

Long-Term Growth Targets Revenue Gross Margins Operating Margins OS aiming for mid single digit growth IC aiming for mid-to-high single digit growth PT aiming for > $250M Maintain at current levels Service v. Geo Pricing pressures mitigated by cost reductions 6-8% 6-8% Proton becomes profitable more Service R&D and SG&A grow slower than Revenue 8-10% Goal: Drive Operating Earnings Faster Than Revenue Double Digit EPS Growth 35 VARIAN MEDICAL SYSTEMS